Neurologist visit frequency was modestly higher among cancer cases than controls but declined over time in both settings, ...

The IND submission includes data from nonclinical pharmacology and toxicology studies, along with manufacturing and quality information, to support initiation of the planned Phase 2 clinical trial.

Advances in diagnostics and disease-modifying therapies have significantly expanded treatment options for MS over the past 2 ...

The ACP received funding to help interpret research and support decisions about MS treatments for older adults with MS.

Multiple sclerosis (MS) has more than doubled in recorded prevalence in England from 2000 to 2020, increasing by 6% per year, largely due to improved diagnosis and longer life expectancy, finds a new ...

Multiple sclerosis prevalence has increased by 6% annually, reaching an estimated 190,000 cases today. New research highlights how improved survival and earlier diagnosis are shaping the MS landscape ...

Despite many efforts over the years, drug developers have not yet secured an FDA approval for a disease-modifying osteoarthritis drug (DMOAD). Biosplice Therapeutics aims to change that with its ...

A research team from the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has found that nitrogen-containing bisphosphonates (NBPs), a ...

Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orziloben orphan drug designation for treatment of intestinal failure-associated liver disease.

Marty Makary, commissioner of the Food and Drug Administration, speaks at the White House on Sept. 22. (Mark Schiefelbein/AP) Marty Makary appeared Thursday for an interview on CNBC to tout efforts ...

Rare diseases have long posed a challenge in the field of medicine. Limited treatment options and diagnostic hurdles mean patient prognosis is often not positive; however, some groundbreaking ...